GCP
VRCA icon

GSA Capital Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

GSA Capital Partners’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,855
Closed -$282K – 2000
2023
Q4 		$282K Buy
3,855
+1,534
+66% +$63K 0.02% 1145
2023
Q3 		$90K Sell
2,321
-1,496
-39% -$76K 0.01% 1394
2023
Q2 		$220K Buy
+3,817
New +$232K 0.02% 1214
2021
Q3 		– Sell
-9,326
Closed -$1.05M – 1806
2021
Q2 		$1.05M Buy
+9,326
New +$1.13M 0.12% 229

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

GSA Capital Partners's VRCA Position: Q1 2024 in Review

GSA Capital Partners sold out of Verrica Pharmaceuticals (VRCA) in Q1 2024, closing a stake of 3,855 shares — an estimated $282K sold.

GSA Capital Partners first reported a position in VRCA in Q2 2021 and held it in 4 quarters. The position peaked at $1.05M in Q2 2021. 60 funds tracked by Wall St. Rank hold VRCA as of Q1 2024.

  • GSA Capital Partners reported no remaining Verrica Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • GSA Capital Partners sold 3,855 Verrica Pharmaceuticals shares in Q1 2024, an estimated $282K.
  • GSA Capital Partners first reported a position in Verrica Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • GSA Capital Partners's Verrica Pharmaceuticals position peaked at $1.05M in Q2 2021.
  • 60 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2024.

Based on GSA Capital Partners's 13F filing for Q1 2024, filed 3 May 2024.